Vertex Pharmaceuticals Toekomstige groei

Future criteriumcontroles 5/6

Vertex Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 47.4% en 8.7% per jaar. De winst per aandeel zal naar verwachting groeien met 47% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 30.6% zijn.

Belangrijke informatie

47.4%

Groei van de winst

47.0%

Groei van de winst per aandeel

Biotechs winstgroei	43.0%
Inkomstengroei	8.7%
Toekomstig rendement op eigen vermogen	30.6%
Dekking van analisten	Good
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:VX1 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	12,924	4,912	5,460	5,873	24
12/31/2025	11,793	4,282	4,756	5,388	33
12/31/2024	10,883	-468	511	307	32
9/30/2024	10,626	-480	-1,351	-843	N/A
6/30/2024	10,337	-490	-1,426	-944	N/A
3/31/2024	10,185	4,019	3,479	3,944	N/A
12/31/2023	9,869	3,620	3,279	3,537	N/A
9/30/2023	9,654	3,470	4,205	4,381	N/A
6/30/2023	9,505	3,365	3,879	4,068	N/A
3/31/2023	9,208	3,260	3,890	4,074	N/A
12/31/2022	8,931	3,322	3,925	4,130	N/A
9/30/2022	8,701	3,273	3,814	4,047	N/A
6/30/2022	8,350	3,195	3,787	4,018	N/A
3/31/2022	7,948	2,451	2,451	2,679	N/A
12/31/2021	7,574	2,342	2,409	2,644	N/A
9/30/2021	7,130	2,176	1,919	2,140	N/A
6/30/2021	6,684	1,992	1,777	2,121	N/A
3/31/2021	6,415	2,762	3,048	3,359	N/A
12/31/2020	6,206	2,712	2,994	3,254	N/A
9/30/2020	5,991	2,691	2,979	3,208	N/A
6/30/2020	5,403	2,081	2,557	2,635	N/A
3/31/2020	4,819	1,511	1,983	2,060	N/A
12/31/2019	4,163	1,177	1,494	1,569	N/A
9/30/2019	3,620	2,144	1,363	1,438	N/A
6/30/2019	3,454	2,215	1,413	1,484	N/A
3/31/2019	3,265	2,155	1,258	1,342	N/A
12/31/2018	3,048	2,096	1,175	1,270	N/A
9/30/2018	2,829	647	1,060	1,183	N/A
6/30/2018	2,623	415	N/A	972	N/A
3/31/2018	2,415	226	N/A	832	N/A
12/31/2017	2,489	263	N/A	845	N/A
9/30/2017	2,296	196	N/A	762	N/A
6/30/2017	2,131	259	N/A	658	N/A
3/31/2017	2,019	177	N/A	517	N/A
12/31/2016	1,702	-112	N/A	236	N/A
9/30/2016	1,661	-219	N/A	121	N/A
6/30/2016	1,557	-275	N/A	-7	N/A
3/31/2016	1,292	-399	N/A	-158	N/A
12/31/2015	1,032	-556	N/A	-365	N/A
9/30/2015	759	-659	N/A	-576	N/A
6/30/2015	628	-734	N/A	-602	N/A
3/31/2015	600	-704	N/A	-620	N/A
12/31/2014	580	-738	N/A	-573	N/A
9/30/2014	787	-582	N/A	-362	N/A
6/30/2014	830	-530	N/A	-289	N/A
3/31/2014	1,002	-428	N/A	-162	N/A
12/31/2013	1,212	-504	N/A	-61	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat VX1 de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 1% ).

Winst versus markt: Er wordt verwacht dat VX1 de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat VX1 binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van VX1 ( 8.7% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van VX1 ( 8.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen VX1 zal naar verwachting over 3 jaar hoog zijn ( 30.6 %)

Vertex Pharmaceuticals Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022

Recent updates

Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023)

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022)

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022)

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022)

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

Insufficient new directors

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022)

Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference

Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021)

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months

Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021)

Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022

Vertex Advances VX-548 in Acute and Neuropathic Pain

Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

Investor sentiment improved over the past week

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference